Equities research analysts forecast that Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) will announce sales of $80,000.00 for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Bellicum Pharmaceuticals’ earnings. The lowest sales estimate is $30,000.00 and the highest is $100,000.00. Bellicum Pharmaceuticals posted sales of $130,000.00 during the same quarter last year, which suggests a negative year over year growth rate of 38.5%. The firm is expected to announce its next quarterly earnings results on Monday, May 14th.
On average, analysts expect that Bellicum Pharmaceuticals will report full-year sales of $310,000.00 for the current financial year, with estimates ranging from $120,000.00 to $400,000.00. For the next financial year, analysts expect that the business will post sales of $570,000.00 per share, with estimates ranging from $300,000.00 to $1.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Bellicum Pharmaceuticals.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last posted its quarterly earnings results on Tuesday, March 13th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.69) by $0.08. The firm had revenue of ($0.07) million for the quarter, compared to analyst estimates of $0.08 million.
Several equities research analysts recently issued reports on the company. BidaskClub raised Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, January 4th. ValuEngine raised Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 3rd. Zacks Investment Research lowered Bellicum Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, January 12th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $10.00 target price (down from $12.00) on shares of Bellicum Pharmaceuticals in a research report on Wednesday, January 31st. Finally, Wells Fargo lowered Bellicum Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $6.00 target price on the stock. in a research report on Wednesday, January 31st. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $17.98.
In other Bellicum Pharmaceuticals news, major shareholder Bros. Advisors Lp Baker sold 880,735 shares of the stock in a transaction on Friday, January 19th. The stock was sold at an average price of $8.20, for a total value of $7,222,027.00. The sale was disclosed in a document filed with the SEC, which is available through this link. 18.77% of the stock is owned by company insiders.
Large investors have recently added to or reduced their stakes in the company. MYDA Advisors LLC bought a new position in shares of Bellicum Pharmaceuticals in the fourth quarter worth $118,000. LPL Financial LLC bought a new position in shares of Bellicum Pharmaceuticals in the fourth quarter worth $140,000. Cubist Systematic Strategies LLC bought a new position in shares of Bellicum Pharmaceuticals in the third quarter worth $164,000. Ellington Management Group LLC bought a new position in shares of Bellicum Pharmaceuticals in the fourth quarter worth $222,000. Finally, Virtus Fund Advisers LLC bought a new position in shares of Bellicum Pharmaceuticals in the fourth quarter worth $343,000. 54.58% of the stock is owned by institutional investors.
BLCM stock opened at $8.26 on Friday. The company has a current ratio of 8.37, a quick ratio of 8.37 and a debt-to-equity ratio of 0.41. The company has a market cap of $301.48, a P/E ratio of -3.16 and a beta of 0.47. Bellicum Pharmaceuticals has a 12-month low of $5.02 and a 12-month high of $14.49.
COPYRIGHT VIOLATION NOTICE: This story was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/17/zacks-brokerages-expect-bellicum-pharmaceuticals-inc-blcm-will-announce-quarterly-sales-of-80000-00.html.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.
Get a free copy of the Zacks research report on Bellicum Pharmaceuticals (BLCM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.